Home Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP
 

Keywords :   


Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP

2014-07-30 10:19:09| drugdiscoveryonline Home Page

Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all

Tags: data study reports drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.11SCR
28.1146
28.11BOSS OD-2 TURBO Over Drive
28.11/ Pulling the Plug
28.11
28.1110
28.112.5 120
28.11MSV-R
More »